Benign Recurrent Intrahepatic Cholestasis Type 1 with Novel Nonsense Mutations in the ATP8B1 Gene
Benign recurrent intrahepatic cholestasis (BRIC) is a group of genetically heterogeneous autosomal recessive liver disorders characterized by recurrent episodes of jaundice and pruritus. BRIC is divided into two groups, BRIC type 1 (BRIC1) and BRIC type 2 (BRIC2), caused by mutations in the ATP8B1 a...
Main Authors: | Ryoichi Miura, Tomokazu Kawaoka, Michio Imamura, Masanari Kosaka, Yusuke Johira, Yuki Shirane, Serami Murakami, Shigeki Yano, Kei Amioka, Kensuke Naruto, Yuwa Ando, Yumi Kosaka, Kenichiro Kodama, Shinsuke Uchikawa, Hatsue Fujino, Atsushi Ono, Takashi Nakahara, Eisuke Murakami, Masami Yamauchi, Takao Hinoi, Hiroshi Aikata |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2022-03-01
|
Series: | Case Reports in Gastroenterology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/522145 |
Similar Items
-
Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
by: Yuwa Ando, et al.
Published: (2022-11-01) -
Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice
by: Yuwa Ando, et al.
Published: (2021-08-01) -
Impact and usefulness of the transition to the new MAFLD classification for non-B, non-C HCC: a retrospective cohort study
by: Yusuke Johira, et al.
Published: (2023-06-01) -
The importance of body composition assessment for patients with advanced hepatocellular carcinoma by bioelectrical impedance analysis in lenvatinib treatment.
by: Kenji Yamaoka, et al.
Published: (2022-01-01) -
Pathological Complete Response to Lenvatinib After Failure of Atezolizumab Plus Bevacizumab in Unresectable Hepatocellular Carcinoma
by: Yusuke Johira, et al.
Published: (2021-11-01)